Morgan Stanley analyst Jeffrey Hung downgrades Cyteir Therapeutics (NASDAQ:CYT) from Equal-Weight to Underweight and lowers the price target from $4 to $2.
BMO Capital analyst James Fotheringham downgrades Focus Finl Partners (NASDAQ:FOCS) from Outperform to Market Perform and lowers the price target from $55 to $53.